|
1
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar
|
|
2
|
Mateyak MK, Obaya AJ and Sedivy JM: c-Myc
regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle
progression at multiple independent points. Mol Cell Biol.
19:4672–4683. 1999. View Article : Google Scholar
|
|
3
|
Prall OW, Sarcevic B, Musgrove EA, Watts
CK and Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2
during G1-S phase progression is accompanied by increased cyclin D1
expression and decreased cyclin-dependent kinase inhibitor
association with cyclin E-Cdk2. J Biol Chem. 272:10882–10894. 1997.
View Article : Google Scholar
|
|
4
|
Pei XH and Xiong Y: Biochemical and
cellular mechanisms of mammalian CDK inhibitors: A few unresolved
issues. Oncogene. 24:2787–2795. 2005. View Article : Google Scholar
|
|
5
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar
|
|
6
|
Benson C, Kaye S, Workman P, Garrett M,
Walton M and de Bono J: Clinical anticancer drug development:
Targeting the cyclin-dependent kinases. Br J Cancer. 92:7–12. 2005.
View Article : Google Scholar
|
|
7
|
Sausville EA: Complexities in the
development of cyclin-dependent kinase inhibitor drugs. Trends Mol
Med. 8(Suppl 4): S32–S37. 2002. View Article : Google Scholar
|
|
8
|
Androutsopoulos V, Wilsher N, Arroo RR and
Potter GA: Bioactivation of the phytoestrogen diosmetin by CYP1
cytochromes 450. Cancer Lett. 274:54–60. 2009. View Article : Google Scholar
|
|
9
|
Liu B, Jia K, Yang Y, Hao S, Lu C, Xu F,
Feng D and Zhu R: Diosmetin induces cell apoptosis by regulating
CYP1A1/CYP1A2 due to 53 activation in HepG2 cells. Protein Pept
Lett. 24:406–412. 2017. View Article : Google Scholar
|
|
10
|
Xu Z, Yan Y, Xiao L, Dai S, Zeng S, Qian
L, Wang L, Yang X, Xiao Y and Gong Z: Radiosensitizing effect of
diosmetin on radioresistant lung cancer cells via Akt signaling
pathway. PLoS One. 12:e01759772017. View Article : Google Scholar
|
|
11
|
Androutsopoulos VP, Mahale S, Arroo RR and
Potter G: Anticancer effects of the flavonoid diosmetin on cell
cycle progression and proliferation of MDA-MB 468 breast cancer
cells due to CYP1 activation. Oncol Rep. 21:1525–1528. 2009.
|
|
12
|
Liu J, Ren H, Liu B, Zhang Q, Li M and Zhu
R: Diosmetin inhibits cell proliferation and induces apoptosis by
regulating autophagy via the mammalian target of rapamycin pathway
in hepatocellular carcinoma HepG2 cells. Oncol Lett. 12:4385–4392.
2016. View Article : Google Scholar
|
|
13
|
Barrajón-Catalán E, Taamalli A,
Quirantes-Piné R, Roldan-Segura C, Arráez-Román D, Segura-Carretero
A, Micol V and Zarrouk M: Differential metabolomic analysis of the
potential antiproliferative mechanism of olive leaf extract on the
JIMT-1 breast cancer cell line. J Pharm Biomed Anal. 105:156–162.
2015. View Article : Google Scholar
|
|
14
|
Ciolino HP, Dankwah M and Yeh GC:
Resistance of MCF-7 cells to dimethylbenz(a)anthracene-induced
apoptosis is due to reduced CYP1A1 expression. Int J Oncol21:.
385–391. 2002.
|
|
15
|
Roma A, Rota SG and Spagnuolo PA:
Diosmetin induces apoptosis of acute myeloid leukemia cells. Mol
Pharm. 15:1353–1360. 2018. View Article : Google Scholar
|
|
16
|
Androutsopoulos VP and Spandidos DA: The
flavonoids diosmetin and luteolin exert synergistic cytostatic
effects in human hepatoma HepG2 cells via CYP1A-catalyzed
metabolism, activation of JNK and ERK and P53/P21 up-regulation. J
Nutr Biochem. 24:496–504. 2013. View Article : Google Scholar
|
|
17
|
Pozarowski P and Darzynkiewicz Z: Analysis
of cell cycle by flow cytometry. Methods Mol Biol. 281:301–311.
2004.
|
|
18
|
Hawksworth D, Ravindranath L, Chen Y,
Furusato B, Sesterhenn IA, McLeod DG, Srivastava S and Petrovics G:
Overexpression of C-MYC oncogene in prostate cancer predicts
biochemical recurrence. Prostate Cancer Prostatic Dis. 13:311–315.
2010. View Article : Google Scholar
|
|
19
|
Chandramohan V, Mineva ND, Burke B, Jeay
S, Wu M, Shen J, Yang W, Hann SR and Sonenshein GE: c-Myc represses
FOXO3a-mediated transcription of the gene encoding the p27(Kip1)
cyclin dependent kinase inhibitor. J Cell Biochem. 104:2091–2106.
2008. View Article : Google Scholar
|
|
20
|
Ferro M, Terracciano D, Buonerba C,
Lucarelli G, Bottero D, Perdonà S, Autorino R, Serino A, Cantiello
F and Damiano R: The emerging role of obesity, diet and lipid
metabolism in prostate cancer. Future Oncol. 13:285–293. 2017.
View Article : Google Scholar
|
|
21
|
de Cobelli O, Terracciano D, Tagliabue E,
Raimondi S, Galasso G, Cioffi A, Cordima G, Musi G, Damiano R,
Cantiello F, et al: Body mass index was associated with upstaging
and upgrading in patients with low-risk prostate cancer who met the
inclusion criteria for active surveillance. Urol Oncol.
33:201.e1–201.e8. 2015. View Article : Google Scholar
|
|
22
|
Barbieri A, Bimonte S, Palma G, Luciano A,
Rea D, Giudice A, Scognamiglio G, La Mantia E, Franco R and Perdonà
S: The stress hormone norepinephrine increases migration of
prostate cancer cells in vitro an in vivo. Int J Oncol. 47:527–534.
2015. View Article : Google Scholar
|
|
23
|
Patel R, Khalifa AO, Isali I and Shukla S:
Prostate cancer susceptibility and growth linked to Y chromosome
genes. Front Biosci (Elite Ed). 10:423–436. 2018.
|
|
24
|
Dickson MA and Schwartz GK: Development of
cell-cycle inhibitors for cancer therapy. Curr Oncol. 16:36–43.
2009.
|
|
25
|
Sandal T: Molecular aspects of the
mammalian cell cycle and cancer. Oncologist. 7:73–81. 2002.
View Article : Google Scholar
|
|
26
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15:1222014. View
Article : Google Scholar
|
|
27
|
Dong P, Maddali MV, Srimani JK, Thélot F,
Nevins JR, Mathey-Prevot B and You L: Division of labour between
Myc and G1 cyclins in cell cycle commitment and pace control. Nat
Commun. 5:47502014. View Article : Google Scholar
|
|
28
|
Peck B, Ferber EC and Schulze A:
Antagonism between FOXO and MYC regulates cellular powerhouse.
Front Oncol. 3:962013. View Article : Google Scholar
|
|
29
|
Tarrado-Castellarnau M, de Atauri P and
Cascante M: Oncogenic regulation of tumor metabolic reprogramming.
Oncotarget. 7:62726–62753. 2016. View Article : Google Scholar
|
|
30
|
Eijkelenboom A, Mokry M, de Wit E, Smits
LM, Polderman PE, van Triest MH, van Boxtel R, Schulze A, de Laat W
and Cuppen E: Genome-wide analysis of FOXO3 mediated transcription
regulation through RNA polymerase II profiling. Mol Syst Biol.
9:6382013. View Article : Google Scholar
|
|
31
|
Ferber EC, Peck B, Delpuech O, Bell GP,
East P and Schulze A: FOXO3a regulates reactive oxygen metabolism
by inhibiting mitochondrial gene expression. Cell Death Differ.
19:968–979. 2012. View Article : Google Scholar
|
|
32
|
Alao JP: The regulation of cyclin D1
degradation: Roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar
|
|
33
|
Mueller A, Odze R, Jenkins TD, Shahsesfaei
A, Nakagawa H, Inomoto T and Rustgi AK: A transgenic mouse model
with cyclin D1 overexpression results in cell cycle, epidermal
growth factor receptor, and p53 abnormalities. Cancer Res.
57:5542–5549. 1997.
|
|
34
|
Besson A, Dowdy SF and Roberts JM: CDK
inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169.
2008. View Article : Google Scholar
|
|
35
|
Hockenbery DM, Oltvai ZN, Yin XM, Milliman
CL and Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to
prevent apoptosis. Cell. 75:241–251. 1993. View Article : Google Scholar
|
|
36
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar
|
|
37
|
Cova D, De Angelis L, Giavarini F,
Palladini G and Perego R: Pharmacokinetics and metabolism of oral
diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol.
30:29–33. 1992.
|
|
38
|
Spanakis M, Kasmas S and Niopas I:
Simultaneous determination of the flavonoid aglycones diosmetin and
hesperetin in human plasma and urine by a validated GC/MS method:
In vivo metabolic reduction of diosmetin to hesperetin. Biomed
Chromatogr. 23:124–131. 2009. View Article : Google Scholar
|
|
39
|
Silvestro L, Tarcomnicu I, Dulea C, Attili
NR, Ciuca V, Peru D and Rizea Savu S: Confirmation of diosmetin
3-O-glucuronide as major metabolite of diosmin in humans, using
micro-liquid-chromatography-mass spectrometry and ion mobility mass
spectrometry. Anal Bioanal Chem. 405:8295–8310. 2013. View Article : Google Scholar
|
|
40
|
Quintieri L, Palatini P, Moro S and
Floreani M: Inhibition of cytochrome P450 2C8-mediated drug
metabolism by the flavonoid diosmetin. Drug Metab Pharmacokinet.
26:559–568. 2011. View Article : Google Scholar
|
